IN2014CN02908A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02908A
IN2014CN02908A IN2908CHN2014A IN2014CN02908A IN 2014CN02908 A IN2014CN02908 A IN 2014CN02908A IN 2908CHN2014 A IN2908CHN2014 A IN 2908CHN2014A IN 2014CN02908 A IN2014CN02908 A IN 2014CN02908A
Authority
IN
India
Prior art keywords
clofazimine
treatment
combination
autoimmune disease
rifabutin
Prior art date
Application number
Inventor
Reza Fathi
Patrick Laughlin Mclean
Harry Jefferson Leighton
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47914967&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN02908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of IN2014CN02908A publication Critical patent/IN2014CN02908A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2

Abstract

A combination of antibiotics including rifabutin clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease said two or more antibiotic agents selected from rifabutin clofazimine and at least one macrolide.
IN2908CHN2014 2011-09-20 2012-09-19 IN2014CN02908A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536824P 2011-09-20 2011-09-20
US201161537229P 2011-09-21 2011-09-21
PCT/IB2012/002252 WO2013041963A2 (en) 2011-09-20 2012-09-19 A composition and method for treating an autoimmune disease

Publications (1)

Publication Number Publication Date
IN2014CN02908A true IN2014CN02908A (en) 2015-07-03

Family

ID=47914967

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2908CHN2014 IN2014CN02908A (en) 2011-09-20 2012-09-19

Country Status (22)

Country Link
US (1) US9901638B2 (en)
EP (1) EP2758061B1 (en)
JP (1) JP6035340B2 (en)
KR (1) KR101987512B1 (en)
CN (1) CN103813797B (en)
AU (1) AU2012311235B2 (en)
BR (1) BR112014006473A2 (en)
CA (1) CA2849255C (en)
CL (1) CL2014000671A1 (en)
DK (1) DK2758061T3 (en)
ES (1) ES2614923T3 (en)
HU (1) HUE032959T2 (en)
IL (1) IL231489A (en)
IN (1) IN2014CN02908A (en)
MX (1) MX347660B (en)
PL (1) PL2758061T3 (en)
PT (1) PT2758061T (en)
RU (1) RU2621129C2 (en)
SG (1) SG11201400386RA (en)
TW (1) TWI573590B (en)
WO (1) WO2013041963A2 (en)
ZA (1) ZA201401954B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910983C (en) * 2013-04-30 2021-11-02 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
US9844540B2 (en) * 2015-10-06 2017-12-19 Redhill Biopharma Ltd. Combination therapies for treating cancer
CU24537B1 (en) 2016-05-02 2021-07-02 Prothena Biosciences Ltd MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY
MA50086A (en) 2017-09-08 2020-07-15 Evelo Biosciences Inc BACTERIAL EXTRACELLULAR (EV) VESICLES
EP4171546A4 (en) * 2020-06-30 2024-03-13 Redhill Biopharma Ltd Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2023182288A1 (en) * 2022-03-22 2023-09-28 国立大学法人京都大学 Drug for treating or preventing charcot-marie-tooth disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0971735T3 (en) 1997-04-01 2008-07-07 Borody Thomas J Methods and compositions for the treatment of inflammatory bowel disease
US7488580B1 (en) 2005-03-10 2009-02-10 University Of Central Florida Research Foundation, Inc. Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
US20080275063A1 (en) 2007-04-24 2008-11-06 Heike Schauerte Inhibitors of protein kinases
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
AU2009212097B2 (en) * 2008-02-08 2013-06-13 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease
WO2011011706A2 (en) 2009-07-24 2011-01-27 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

Also Published As

Publication number Publication date
EP2758061B1 (en) 2016-11-16
CA2849255A1 (en) 2013-03-28
EP2758061A4 (en) 2015-02-25
JP6035340B2 (en) 2016-11-30
IL231489A (en) 2017-01-31
MX2014003430A (en) 2014-07-28
BR112014006473A2 (en) 2017-03-28
ES2614923T3 (en) 2017-06-02
KR101987512B1 (en) 2019-06-10
CN103813797B (en) 2017-07-11
CN103813797A (en) 2014-05-21
JP2014526548A (en) 2014-10-06
US9901638B2 (en) 2018-02-27
KR20140082982A (en) 2014-07-03
WO2013041963A3 (en) 2013-06-06
PT2758061T (en) 2017-02-14
CA2849255C (en) 2019-06-04
RU2014115807A (en) 2015-10-27
SG11201400386RA (en) 2014-09-26
CL2014000671A1 (en) 2014-10-03
IL231489A0 (en) 2014-04-30
EP2758061A2 (en) 2014-07-30
WO2013041963A2 (en) 2013-03-28
RU2621129C2 (en) 2017-05-31
DK2758061T3 (en) 2017-02-20
MX347660B (en) 2017-05-08
AU2012311235B2 (en) 2017-02-02
ZA201401954B (en) 2016-06-29
HUE032959T2 (en) 2017-11-28
AU2012311235A1 (en) 2014-03-20
PL2758061T3 (en) 2017-08-31
TWI573590B (en) 2017-03-11
TW201320999A (en) 2013-06-01
US20140228307A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
IN2014CN02908A (en)
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
PH12016500024A1 (en) Bromodomain inhibitor
ECSP12012349A (en) APOPTOSIS INDUCTIVE AGENTS AGAINST CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
ECSP12012348A (en) APOPTOSIS INDUCTIVE AGENTS AGAINST CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
NZ713615A (en) Methods for treating bacterial infections
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
MX346224B (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
MX2015006681A (en) Stabilized vancomycin formulations.
IN2014CN03465A (en)
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
MY175800A (en) Combination treatment of cancer
ZA201105290B (en) Antibiotic compositions for the treatment of gram negative infections
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
TN2014000009A1 (en) Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
MX2009009153A (en) Pyrano-pyrazole-amines.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
CL2013001482A1 (en) Compounds derived from 3-methyl-7-oxo-4-thia-1-aza-bicyclo [3.2.0] heptane for use in inhibiting beta-lactamases produced by bacteria and restoring / enhancing the activity of antibiotics; and pharmaceutical composition that includes them.
UA107095C2 (en) ANTIBIOTIC MICROPARTICLES FOR INHALATION
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
TW200640942A (en) New macrolides
MX2014001623A (en) Use of cardiotrophin-1 for the treatment of kidney diseases.
CL2008003933A1 (en) Compounds derived from n-heterocyclo- [1,2-a] -pyridine-2-carboxamide; preparation procedure; pharmaceutical composition; Useful in the treatment and / or prevention of neurodegenerative and inflammatory diseases, epilepsy, osteoporosis, malignant tumors, among others.